Spyre Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

• Spyre Therapeutics Inc reported a quarterly adjusted loss of 94 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -15 cents. The mean expectation of fourteen analysts for the quarter was for a loss of 83 cents per share. Wall Street expected results to range from $-1.53 to -57 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Spyre Therapeutics Inc's reported EPS for the quarter was a loss of 94 cents​.

• The company reported a quarterly loss of $96.12 million.

• Spyre Therapeutics Inc shares had risen by 7.3% this quarter and gained 191.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 8.1% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Spyre Therapeutics Inc is $123.00, about 22.3% above its last closing price of $95.51

This summary was machine generated from LSEG data November 3 at 09:34 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)